"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...

The candidates merge two existing vaccines that have demonstrated favourable tolerability through randomised controlled ...

Sanofi CEO Paul Hudson says, "AI is a huge opportunity, and we can't be deniers." ...

The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates ...

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...

Big Pharma-backed immunomodulation biotech Nuvig Therapeutics is moving its lead asset into phase 2 trials using a $161 ...

A drug developed by Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder ...

Sanofi reports positive Phase III results for its BTK inhibitor in treating immune thrombocytopenia, demonstrating faster ...

Paris: The US Food and Drug Administration (USFDA) has granted Fast Track designation to two Sanofi combination vaccine ...

Chinese authorities rolled out the red carpet for French pharmaceutical and healthcare giant Sanofi, which plans to invest around 1 billion euros (US$1.05 billion) to build a new insulin plant in ...

Sanofi has announced plans to invest approximately €1bn to build a new insulin production base in China.

SHANGHAI, Dec 2 (Reuters) - Sanofi plans to invest around 1 billion euros ($1.05 billion) to build a new insulin production ...